Registration Dossier

Data platform availability banner - registered substances factsheets

Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.

The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.

Diss Factsheets

Toxicological information

Repeated dose toxicity: oral

Currently viewing:

Administrative data

Endpoint:
repeated dose toxicity: oral, other
Remarks:
Combined Repeated Dose Toxicity Study with the Reproduction/Developmental Toxicity Screening Test
Type of information:
experimental study
Adequacy of study:
weight of evidence
Reliability:
4 (not assignable)
Rationale for reliability incl. deficiencies:
secondary literature
Justification for type of information:
Data is from secondary source.

Data source

Reference
Reference Type:
secondary source
Title:
Combined Repeated Dose Toxicity Study with the Reproduction/Developmental Toxicity Screening Test in Wistar Rats with test chemical
Author:
USEPA
Year:
2012
Bibliographic source:
BASF Corporation, OTS0601595 United States Environmental Protection Agency, 2012

Materials and methods

Test guideline
Qualifier:
according to guideline
Guideline:
OECD Guideline 422 (Combined Repeated Dose Toxicity Study with the Reproduction / Developmental Toxicity Screening Test)
Principles of method if other than guideline:
In order to evaluate the toxicity of test chemical Combined Repeated Dose Toxicity Study with the Reproduction/Developmental Toxicity Screening Test was conducted in male and female Wistar Rats.
GLP compliance:
not specified
Limit test:
no

Test material

Constituent 1
Chemical structure
Reference substance name:
Reference substance 002
Cas Number:
770661-17-1
Molecular formula:
C35H46N5O4
Constituent 2
Chemical structure
Reference substance name:
Reference substance 001
Cas Number:
16887-00-6
Molecular formula:
Cl
Test material form:
liquid
Details on test material:
- Name of test material : Reaction mass of 1-​Propanaminium, 3-​[[2-​cyano-​3-​[4-​(diethylamino)​phenyl]​-​1-​oxo-​2-​propen-​1-​yl]​oxy]​-​N-​[2-​[[2-​cyano-​3-​[4-​(diethylamino)​phenyl]​-​1-​oxo-​2-​propen-​1-​yl]​oxy]​ethyl]​-​N,​N-​dimethyl-​ & chloride- Molecular formula : C35H46ClN5O4- Molecular weight : 636.232 g/mol- Smiles notation : C(CCOC(\C(=C\c1ccc(cc1)N(CC)CC)C#N)=O)[N+](C)(C)CCOC(\C(=C\c1ccc(cc1)N(CC)CC)C#N)=O.[ClH-]- InChl : 1S/C35H46N5O4.ClH/c1-7-38(8-2)32-16-12-28(13-17-32)24-30(26-36)34(41)43-22-11-20-40(5,6)21-23-44-35(42)31(27-37)25-29-14-18-33(19-15-29)39(9-3)10-4;/h12-19,24-25H,7-11,20-23H2,1-6H3;1H/q+1;/p-1/b30-24+,31-25+;- Substance type: Organic- Physical state: Liquid
Specific details on test material used for the study:
- Name of test material : Reaction mass of 1-​Propanaminium, 3-​[[2-​cyano-​3-​[4-​(diethylamino)​phenyl]​-​1-​oxo-​2-​propen-​1-​yl]​oxy]​-​N-​[2-​[[2-​cyano-​3-​[4-​(diethylamino)​phenyl]​-​1-​oxo-​2-​propen-​1-​yl]​oxy]​ethyl]​-​N,​N-​dimethyl-​ & chloride- Molecular formula : C35H46ClN5O4- Molecular weight : 636.232 g/mol- Smiles notation : C(CCOC(\C(=C\c1ccc(cc1)N(CC)CC)C#N)=O)[N+](C)(C)CCOC(\C(=C\c1ccc(cc1)N(CC)CC)C#N)=O.[ClH-]- InChl : 1S/C35H46N5O4.ClH/c1-7-38(8-2)32-16-12-28(13-17-32)24-30(26-36)34(41)43-22-11-20-40(5,6)21-23-44-35(42)31(27-37)25-29-14-18-33(19-15-29)39(9-3)10-4;/h12-19,24-25H,7-11,20-23H2,1-6H3;1H/q+1;/p-1/b30-24+,31-25+;- Substance type: Organic- Physical state: Liquid

Test animals

Species:
rat
Strain:
Wistar
Sex:
male/female
Details on test animals or test system and environmental conditions:
Not specified

Administration / exposure

Route of administration:
oral: gavage
Vehicle:
not specified
Analytical verification of doses or concentrations:
not specified
Duration of treatment / exposure:
28 days for male 55 days for female
Frequency of treatment:
Daily
Doses / concentrations
Remarks:
0,100, 300 and 1000 mg/kg bw/day
No. of animals per sex per dose:
Not specified
Control animals:
yes, concurrent vehicle
Details on study design:
Not specified
Positive control:
Not specified

Examinations

Observations and examinations performed and frequency:
CAGE SIDE OBSERVATIONS: Yes DETAILED CLINICAL OBSERVATIONS: Yes BODY WEIGHT: Not specified FOOD CONSUMPTION AND COMPOUND INTAKE (if feeding study):- Food consumption for each animal determined and mean daily diet consumption calculated as g food/kg body weight/day: Not specified - Compound intake calculated as time-weighted averages from the consumption and body weight gain data: Not specified FOOD EFFICIENCY:- Body weight gain in kg/food consumption in kg per unit time X 100 calculated as time-weighted averages from the consumption and body weight gain data: Not specified WATER CONSUMPTION AND COMPOUND INTAKE (if drinking water study): Not specified OPHTHALMOSCOPIC EXAMINATION: Not specified HAEMATOLOGY: Not specified CLINICAL CHEMISTRY: Yes ,Parameters such as creatinine, urea and potassium level were observedURINALYSIS: Not specified NEUROBEHAVIOURAL EXAMINATION: Not specified
Sacrifice and pathology:
GROSS PATHOLOGY: Yes, the male animals were necropsied after 28 days of administration of test chemical.HISTOPATHOLOGY: Yes , Animals were observed microscopically.

Results and discussion

Results of examinations

Clinical signs:
no effects observed
Description (incidence and severity):
No significant effect was observed at dose level of 0,100, 300 and 1000 mg/kg bw/day in treated group compare to control.
Mortality:
no mortality observed
Description (incidence):
No significant effect was observed at dose level of 0,100, 300 and 1000 mg/kg bw/day in treated group compare to control.
Body weight and weight changes:
not specified
Food consumption and compound intake (if feeding study):
not specified
Food efficiency:
not specified
Water consumption and compound intake (if drinking water study):
not specified
Ophthalmological findings:
not specified
Haematological findings:
not specified
Clinical biochemistry findings:
effects observed, treatment-related
Description (incidence and severity):
Significant increase in creatinine levels were observed at the dose level of 1000 mg/kg bw/day in treated group compare to control.Even Increased urea and potassium levels were observed at the dose level of 1000 mg/kg bw/day in treated female group compare to control.
Urinalysis findings:
not specified
Behaviour (functional findings):
not specified
Immunological findings:
not specified
Organ weight findings including organ / body weight ratios:
not specified
Gross pathological findings:
not specified
Neuropathological findings:
not specified
Histopathological findings: non-neoplastic:
effects observed, treatment-related
Description (incidence and severity):
Minimally increased occurrence of single cell necrosis or apoptosis in the liver of six males and three females were observed at the dose level of 1000 mg/kg bw/day in treated group compare to control.
Histopathological findings: neoplastic:
not specified
Other effects:
not specified

Effect levels

Dose descriptor:
NOAEL
Effect level:
300 other: mg/kg/day
Based on:
test mat.
Sex:
male/female
Basis for effect level:
other: No significant effect was observed at this dose.

Target system / organ toxicity

Critical effects observed:
not specified
Treatment related:
not specified
Dose response relationship:
not specified
Relevant for humans:
not specified

Applicant's summary and conclusion

Conclusions:
NOAEL was considered to be 300 mg/kg/day in Wistar male and female rats, when they were treated withReaction mass of 1-Propanaminium, 3-[[2-cyano-3-[4-(diethylamino)phenyl]-1-oxo-2-propen-1-yl]oxy]-N-[2-[[2-cyano-3-[4-(diethylamino)phenyl]-1-oxo-2-propen-1-yl]oxy]ethyl]-N,N-dimethyl- & chloride by oral gavage for subchronic study.
Executive summary:

In a Combined Repeated Dose Toxicity Study with the Reproduction/Developmental Toxicity Screening Test was conducted for test chemical by OECD guideline 422.The test chemical was exposed to Wistar male and female rat were in the concentration of 0, 100, 300 and 1000 mg/kg bw/day by oral gavage for 56 days .  The animals were observed for mortality, clinical sign, clinical chemistry, gross pathology and histopathology. Increased creatinine levels were observed in male and female rats while increased urea and potassium levels in female rats at dose level of 1000 mg/kg/day. In addition, minimal increased occurrence of single cell necrosis or apoptosis in the liver of six males and three females at 1000 mg/kg/day were observed. No significant adverse effect at 100 and 300 mg/kg bw was observed. Therefore NOAEL was considered to be 300 mg/kg/day in Wistar male and female rats, when they were treated with test chemical by oral gavage for subchronic study.